Kura Oncology (NASDAQ:KURA) COO Sells $72,513.00 in Stock

Posted by Stanley Muller on Oct 2nd, 2026

Kura Oncology, Inc. (NASDAQ:KURA – Get Free Report) COO Kathleen Ford sold 6,906 shares of Kura Oncology stock in a transaction that occurred on Monday, September 28th. The shares were sold at an average price of $10.50, for a total transaction of $72,513.00. Following the sale, the chief operating officer owned 146,654 shares in the company, valued at $1,539,867. This represents a 4.50% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Kathleen Ford also recently made the following trade(s):

On Tuesday, September 29th, Kathleen Ford sold 3,668 shares of Kura Oncology stock. The stock was sold at an average price of $10.75, for a total transaction of $39,431.00.

Kura Oncology Price Performance

Shares of KURA stock opened at $10.65 on Friday. The firm has a fifty day simple moving average of $11.23 and a 200-day simple moving average of $10.19. The company has a market capitalization of $947.42 million, a PE ratio of -3.16 and a beta of 0.47. Kura Oncology, Inc. has a twelve month low of $7.36 and a twelve month high of $13.90. The company has a current ratio of 4.73, a quick ratio of 4.71 and a debt-to-equity ratio of 0.12.

Kura Oncology (NASDAQ:KURA – Get Free Report) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($0.77) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.88) by $0.11. Kura Oncology had a negative net margin of 384.30% and a negative return on equity of 207.18%. The firm had revenue of $20.87 million for the quarter, compared to the consensus estimate of $20.16 million. Equities research analysts anticipate that Kura Oncology, Inc. will post -3.25 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Kura Oncology

Several large investors have recently added to or reduced their stakes in KURA. Tidal Investments LLC bought a new position in Kura Oncology during the second quarter worth $1,029,000. WINTON GROUP Ltd raised its holdings in shares of Kura Oncology by 26.2% during the second quarter. WINTON GROUP Ltd now owns 13,000 shares of the company’s stock worth $143,000 after purchasing an additional 2,700 shares during the period. Integrated Wealth Concepts LLC bought a new position in shares of Kura Oncology in the 2nd quarter worth about $159,000. IFP Advisors Inc lifted its position in shares of Kura Oncology by 136.5% in the 2nd quarter. IFP Advisors Inc now owns 2,542 shares of the company’s stock worth $28,000 after buying an additional 1,467 shares during the last quarter. Finally, Allworth Financial LP boosted its holdings in shares of Kura Oncology by 148.4% in the 2nd quarter. Allworth Financial LP now owns 10,326 shares of the company’s stock valued at $113,000 after buying an additional 6,169 shares during the period.

Key Kura Oncology News

Here are the key news stories impacting Kura Oncology this week:

Positive Sentiment: JPMorgan initiated coverage of Kura Oncology with an “overweight” rating and a $30 price target, implying substantial upside from recent trading levels. The firm views Kura as a promising precision-cancer-medicine developer, particularly because of its menin-inhibitor platform and lead program, ziftomenib, for genetically defined acute myeloid leukemia. JPMorgan Kura Oncology rating article
Positive Sentiment: CNBC highlighted JPMorgan’s view that KURA could nearly triple, reinforcing the potential valuation impact of successful clinical and regulatory execution. The bullish outlook is particularly important for a biotechnology stock trading below the average analyst target of approximately $25.40. CNBC Kura Oncology analyst outlook
Neutral Sentiment: Kura’s financial position remains relatively liquid, with a reported quick ratio of 4.71 and current ratio of 4.73, but the company remains unprofitable and analysts expect a significant full-year loss. That means the stock’s valuation continues to depend heavily on clinical progress rather than current earnings.
Negative Sentiment: Multiple insiders, including executives Kathleen Ford, Brian Powl, Mollie Leoni, Thomas Doyle and Teresa Bair, sold shares in late September and October 1. The reported transactions represent roughly 97,000 shares and more than $1 million in proceeds, creating a potential near-term overhang. The sales do not necessarily indicate deteriorating business prospects, since the insiders retained meaningful holdings, but they may weigh on investor confidence. Kura Oncology insider sales

Analyst Upgrades and Downgrades

Several research firms recently commented on KURA. Weiss Ratings reiterated a “sell (d-)” rating on shares of Kura Oncology in a research note on Friday, July 17th. Raymond James Financial set a $24.00 price objective on Kura Oncology in a report on Monday, August 24th. Wedbush upped their target price on Kura Oncology from $36.00 to $38.00 and gave the company an “outperform” rating in a research report on Thursday, August 13th. JPMorgan Chase & Co. assumed coverage on Kura Oncology in a research note on Thursday. They set an “overweight” rating and a $30.00 target price for the company. Finally, Wells Fargo & Company set a $24.00 price target on shares of Kura Oncology in a research report on Thursday, June 4th. Eleven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $25.69.

View Our Latest Report on KURA

Kura Oncology Company Profile

(Get Free Report)

Kura Oncology, Inc is a biopharmaceutical company focused on developing precision medicines for the treatment of cancer. The company’s research programs target specific genetic and molecular abnormalities that contribute to tumor growth, with an emphasis on hematologic malignancies and selected solid tumors.

Kura’s leading program has been ziftomenib, an oral, selective menin inhibitor being developed for genetically defined forms of acute myeloid leukemia, including cancers with NPM1 mutations or certain KMT2A rearrangements.